Results 41 to 50 of about 23,301 (196)
Update on mantle cell lymphoma [PDF]
Blood, 2018 AbstractMantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that is most commonly treated with combination chemo-immunotherapy at diagnosis because of the poor prognosis. More indolent presentations have been described including patients who can defer initial therapy without adverse impact on survival.
openaire +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin +4 more
wiley +1 more source
Rare Tumors, 2015 We present a case of a pleural space malignancy masked by an atypical presentation of mantle cell lymphoma. Our patient presented with a large pleural effusion and right sided pleural studding, initially attributed to a new diagnosis of mantle cell ...
Luke Masha +2 more
doaj +1 more source
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley +1 more source
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Journal of Hematology & Oncology, 2018 Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji +5 more
doaj +1 more source
Neuroprotection, EarlyView.Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji +4 more
wiley +1 more source
EJNMMI Research, 2020 Background In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with ...
Qingqing Pan +7 more
doaj +1 more source
Radioimmunotherapy in mantle cell lymphoma [PDF]
Best Practice & Research Clinical Haematology, 2012 Mantle cell lymphoma (MCL), though characterized by the chromosomal translocation t(11; 14) (q13; q32), is a heterogeneous disease. Often termed an aggressive lymphoma in the U.S., but included in indolent lymphoma trials in Europe, MCL is not curable with standard immuno-chemotherapy.
Alan P, Skarbnik, Mitchell R, Smith
openaire +2 more sources
The pathologic diagnosis of mantle cell lymphoma.
Histology and histopathology, 2021 Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and Cyclin D1 over expression. A very small subset of MCL may lack the t(11;14) (q13;q32) translocation and Cyclin D1 over expression, but show alternative translocations involving CCND2 and CCND3, and over expression ...
Li, Shaoying, Xu, Jie, You, James
openaire +2 more sources
Respirology, EarlyView.We assessed the diagnostic yield of EBUS‐guided transbronchial mediastinal cryobiopsy (EBUS‐TBMC) compared with EBUS‐transbronchial needle aspiration (EBUS‐TBNA) in patients with suspected mediastinal lymphoproliferative disorders (LPDs). EBUS‐TBMC was superior to EBUS‐TBNA and achieved a high diagnostic yield in patients with suspected mediastinal ...
Yaniv Dotan +12 more
wiley +1 more source